Psilocybin for Treatment-Resistant Depression

NCT ID: NCT05029466

Last Updated: 2023-07-27

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE2
• Total Enrollment: 30 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2021-11-19
• Study Completion Date: 2023-07-22

Brief Summary

The purpose of this study is to see if psilocybin, an investigational drug, is safe and well tolerated. Researchers also want to know if psilocybin can improve symptoms of depression. This study will see if psilocybin is safe and well tolerated by tracking changes in suicidal thoughts and behaviour, monitoring if any participants choose to stop participating in the study, and measuring any serious side effects, as well as how long they take to resolve. This study will also see if depression symptoms improve (or worsen) after psilocybin is administered. Additional information about participants' depressive symptoms and side effects will also be measured during the study.

Detailed Description

This randomized clinical trial will assess the feasibility, safety, and efficacy of single and repeat doses of psilocybin at point-of-care in persons with treatment-resistant depression as part of major depressive disorder or bipolar II disorder. The primary objective is to evaluate the feasibility of psilocybin in adults with treatment-resistant depression. The secondary objectives are to assess the efficacy and tolerability of psilocybin at point-of-care.

Conditions

Treatment Resistant Depression

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Immediate treatment

Participants will commence psilocybin treatment immediately upon study enrollment.

Group Type: EXPERIMENTAL

Psilocybin

Intervention Type: DRUG

Participants will receive a single dose of psilocybin and be assessed weekly for six weeks and biweekly for 18 weeks. Participants who relapse may receive up to two repeated doses of psilocybin.

Delayed treatment

Participants will commence psilocybin treatment two weeks after study enrollment.

Group Type: EXPERIMENTAL

Psilocybin

Intervention Type: DRUG

Participants will receive a single dose of psilocybin and be assessed weekly for six weeks and biweekly for 18 weeks. Participants who relapse may receive up to two repeated doses of psilocybin.

Interventions

Psilocybin

Participants will receive a single dose of psilocybin and be assessed weekly for six weeks and biweekly for 18 weeks. Participants who relapse may receive up to two repeated doses of psilocybin.

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

1. Over the age of 18 years and under the age of 65;

2. Diagnosed with major depressive disorder or bipolar II disorder by a healthcare provider;

3. Experiencing a major depressive episode (MDE) without psychotic features as defined and operationalized in the DSM-5, where the duration of the current episode is at least 3 months;

4. Have failed to respond to an adequate dose and duration of at least two guideline-concordant pharmacological treatments for the current MDE, as determined by the Massachusetts General Hospital-Antidepressant Treatment History Questionnaire; and

5. Able to complete all protocol required assessment tools without any assistance or alteration to the copyrighted assessments, and to comply with all study visits.

Individuals meeting one or more of the following DSM-5-defined criteria will be excluded:

• Current or past history of bipolar I disorder, schizophrenia, psychotic disorder, delusional disorder, paranoid personality disorder, or schizoaffective disorder, as assessed by a structured clinical interview (MINI) and International Personality Disorder Examination (IPDE);
• First degree history of schizophrenia or any psychotic disorders, including bipolar disorder with psychotic features;
• Currently experiencing symptoms of hypomania or mania as measured by the Young Mania Rating Scale (YMRS) total score > 12;
• History of a hypomanic or manic episode in the past 3 months;
• History of substance use and/or alcohol use disorder, of moderate severity or greater, in the past 3 months;
• Lifetime history of substance use disorder with a hallucinogen;
• Lifetime history of substance-induced psychosis;
• Currently experiencing psychotic symptoms as part of an MDE (mood congruent/mood incongruent).

Individuals meeting one or more of the following criteria will also be excluded:

• Exposure to psilocybin or any other psychedelic in the past 12 months prior to screening and/or during the current MDE;
• Uncontrolled or insulin-dependent diabetes;
• Seizure disorder;
• Other personal circumstances or behaviour judged to be incompatible with establishment of rapport or safe exposure to psilocybin;
• Women who are pregnant (self-report or via urine test), nursing, or planning a pregnancy;
• Refusal to use an effective contraceptive method by the participant or participant's partner (i.e., combined estrogen- and progestogen-containing hormonal contraception or progestogen-only hormonal contraception with inhibition of ovulation; intrauterine device; intrauterine hormone-releasing system; bilateral tubal occlusion; vasectomized partner; sexual abstinence) throughout their participation in the study;
• Recent stroke (< 1 year from signing of ICF), recent myocardial infarction (< 1 year from signing of ICF), uncontrolled hypertension (blood pressure > 140/90 mmHg) or clinically significant arrhythmia within 1 year of signing the ICF;
• Positive urine drug screen for illicit drugs or drugs of abuse at screening, a week prior to treatment, and during the trial (any positive urine drug test will be reviewed with participants to determine the pattern of use and eligibility will be determined at the investigator's discretion);
• Current enrolment in any investigational drug or device study or participation in such within 30 days of screening;
• Current enrolment in an interventional study for depression or participation in such within 30 days of screening;
• Abnormal and clinically significant results on the physical examination, vital signs, ECG, or laboratory tests at screening;
• Any other clinically significant cardiovascular, pulmonary, gastrointestinal, hepatic, renal or any other major concurrent illness that, in the opinion of the investigator, may interfere with the interpretation of the study results or constitute a health risk for the participant if he/she takes part in the study.

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 65 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Braxia Scientific Corp.

UNKNOWN

Sponsor Role: collaborator

Usona Institute

OTHER

Sponsor Role: collaborator

Brain and Cognition Discovery Foundation

OTHER

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Joshua D Rosenblat, MD, MSc

Role: PRINCIPAL_INVESTIGATOR

Canadian Rapid Treatment Centre of Excellence

Locations

Canadian Rapid Treatment Centre of Excellence (CRTCE)

Mississauga, Ontario, Canada

Countries

Canada

References

Rosenblat JD, Meshkat S, Doyle Z, Kaczmarek E, Brudner RM, Kratiuk K, Mansur RB, Schulz-Quach C, Sethi R, Abate A, Ali S, Bawks J, Blainey MG, Brietzke E, Cronin V, Danilewitz J, Dhawan S, Di Fonzo A, Di Fonzo M, Drzadzewski P, Dunlop W, Fiszter H, Gomes FA, Grewal S, Leon-Carlyle M, McCallum M, Mofidi N, Offman H, Riva-Cambrin J, Schmidt J, Smolkin M, Quinn JM, Zumrova A, Marlborough M, McIntyre RS. Psilocybin-assisted psychotherapy for treatment resistant depression: A randomized clinical trial evaluating repeated doses of psilocybin. Med. 2024 Mar 8;5(3):190-200.e5. doi: 10.1016/j.medj.2024.01.005. Epub 2024 Feb 14.

Reference Type: DERIVED

PMID: 38359838 (View on PubMed)

Other Identifiers

253490

Identifier Type: -

Identifier Source: org_study_id